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Polymerization of normal and intact J2-microgIobuIin as the amyloi-
dogenic protein in dialysis-amyloidosis. The primary structure of 13,-
microglobulin (132m), the major constituent protein of 132-microglobulin
amyloidosis (A132m) or dialysis-amyloidosis, was initially shown to be
identical to serum 132m, thereby strongly suggesting the polymerization of
intact f32m in tissues. Recent biochemical data have been controversial,
showing 132m acidic isoforms, fragmentation and amino acid sequence
alteration of deposited 132m. The aim of this study was to reinvestigate f32m
amyloid deposits for the presence of 132m fragments and/or amino acid
sequence alteration. Four amyloid-laden tissues (3 femoral bone amyloid
cysts and I heart tissue) from dialysis patients were used to isolate
amyloidogenic 132m. Amyloid fibrils were isolated using the classic water
extraction method, and purified in 6 at guanidine on a gel-filtration
column. The protein was further purified on 17% SDS-PAGE gel, and
transferred to a nitrocellulose membrane for immunostaining with anti-
human 13,m. 132m samples were microsequenced using the standard
O3RPTH program on a 470A gas-phase sequencer, and HPLC was
performed after digestion with trypsin. Two peaks were obtained with the
gel filtration column, the second corresponding by molecular weight to
32m. SDS-PAGE analysis of this peak under reducing conditions, dem-
onstrated one major band at 12,000 Da and a minor band at 25,000 Da
(monomer and dimer), and no lower molecular weight bands were
observed. The 12 kDa band was micro-sequenced and the amino acid
sequence corresponded to that of normal f32m through the 40th residue.
Amino acid sequence analysis showed no difference from normal 132m in
any of the f32m proteins contained in the amyloid deposits isolated from
the four studied tissues. Also, the HPLC profile of the four protein
samples were strictly normal and identical to a commercial preparation of
132m. The present study demonstrates that 132m molecules polymerized in
amyloid fibrils and deposits are intact and have a normal amino acid
sequence, and produced by a specific and unique fibrillogenetic mecha-
nism, which does not require proteolytic processing from the precursor
protein to the amyloid fibrils.
132-microglobulin amyloidosis (A132m) has become recognized
as a frequent chronic complication in long-term dialysis patients
[1, 2]. The incidence increases progressively with years on dialysis,
reaching almost 80% in patients dialyzed over 15 years [3]. The
main clinical manifestations are rheumatological disorders includ-
ing carpal tunnel syndrome, chronic synovitis, progressive bone
destruction and pathological fractures, but systemic and visceral
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involvement have also been reported [4—6]. In 1985, J32-micro-
globulin (132m) was identified as the major constituent protein of
this unique type of systemic amyloidosis [7—9]. The specific
pathogenesis of A/32m remains unknown, although 132m has
clearly been identified as playing a central role as the amyloido-
genie protein.
The primary structure of the amyloid protein was initially
shown to be identical to normal f32m, strongly suggesting the
polymerization of intact 132m in tissues [9, 10]. Immunoblot
analysis of partially solubilized amyloid substance from bone
lesion suggested that tissue deposits are composed essentially of
monomers, as well as some dimers, and higher polymers of f32m.
This finding is relevant since the precursor amyloid protein is
biochemically identical to the deposited protein, differentiating
the A/32m amyloidogenesis process from other types of amyloid-
oses, in which a proteolytic process is suspected for the precursor
protein to form the fibrillar amyloid protein (AA, AL) [11].
Subsequent biochemical data have been controversial in defin-
ing the nature of the f32m deposited in amyloid fibrils and the
fibrillogenetic process required. Linke et al reported a lysine-
specific proteolytic cleavage of the N-terminal in the 132m isolated
from amyloid deposits (renal calculus, carpal synovia and femoral
head), although using monoclonal antibodies against these 132m-
fragments (P132) they could only demonstrate 132m fragmentation
in renal calculus [12, 13]. Ogawa et al described the presence of a
novel 132m isoform in dialysis patients, specific for dialysis-amy-
loidosis [14]. The analysis of this novel isoform demonstrated the
replacement of an aspartic acid by a asparagine at 17th residue,
and suggested that this deamination would be responsible for the
arnyloidogenicity of 2m [151. Several authors confirmed the
presence of different 132m isoforms in the serum of dialysis
patients, although these more acidic isoforms of f32m arc not
specific for amyloid deposits [16—20]. Also, Miyata et al recently
demonstrated that the acidic 132m is generated by modification
with advanced glycation end products (AGEs), implicating a
potential link of this modified 132m to the pathogenesis of
dialysis-amyloidosis [20, 21].
The aim of the present study was to define the biochemical
characteristics of the 2m deposited in several amyloid deposits
from dialysis patients, and to reinvestigate the presence of 13,m
fragments and/or alterations in the amino acid sequence of the
amyloidogenic /32m.
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Table 1. Clinical data from the four studied patients
Case 1 Case 2 Case 3 Case 4
Gender Male Male Female Male
Age years 56 60 62 58
Renal disease Chronic
glomerulopathy
Nephrosclerosis APKD APKD
Time on 11 15 13 12
dialysis years
Clinical CTS Bill CTS Unil CTS Bil CTS Bil
data AA AA AA AA
A2m SP Visceral
Tissue Gelatinous
brown mass
femoral head
Femoral
hone
marrow
Femoral
bone
marrow
Heart
Amount 1.8g 12g 9g 50g
Congo red positive positive positive positive
IH-3,m +++ +++ +++ +++
Abbreviations are: PKD, polycystic kidney disease; CTS, carpal tunnel
syndrome; AA, amyloid arthropathy; SP, amyloid spondyloarthropathy;
IH, immunohistochemical studies.
Methods
Clinical material
Tissues from four patients with end-stage renal disease on
hemodialysis treatment were examined. The mean age of the
patients was 59 2.8 years old with a mean time on hemodialysis
of 12.7 1.7 years. Hemodialysis was performed three times
weekly, with polyacrilonitrile membranes (AN-69) in three pa-
tients and cuprophane membranes in one, without re-use. The
etiologies of the primary renal disease leading to chronic renal
failure included chronic glomerulopathy (1 case), nephrosclerosis
(1 case), and adult polycystic kidney disease (2 cases). All four
patients were affected clinically by Af32m amyloidosis (carpal
tunnel syndrome, amyloid arthropathy and/or destructive spondy-
Ioarthropathy), and histologically demonstrated amyloid flbrils in
carpal synovium and/or in synovial fluid or biopsy of the knee and
shoulder (Table 1). Patient #4 died secondary to a refractory
heart failure.
The amyloid-laden tissues from the four patients included: a
gelatinous brown mass (1.8 g) from an aniyloidoma of the femoral
head, two femoral bone marrows (12 and 9 g), and a piece of heart
(50 g). Femoral tissues were obtained during hip replacement for
pathological femur neck fracture, and the heart was obtained at
autopsy. All specimens were immediately frozen at —70°C, until
they were processed. Routine paraffin sections of the three tissues
were used to confirm the presence of massive amyloid deposits
(Congo red positive), and the /32m nature of the amyloid sub-
stance.
A f32m isolation
Amyloid fibrils were purified from the tissues using the classic
water extraction method [22J. The amyloid fibril fraction con-
tained more than 75% amyloid, according to examination of
material dried Ofl glass slides (stained with Congo red and
hematoxylin and examined on polarized light). Thirty to 60 mg of
amyloid fibrils were suspended in 3 ml of 6 M guanidine, 0.1 M Tris
and 0.17 M DTT pH 7.6, centrifuged at 15,000 rpm for 50 minutes.
Approximately 25% of the initial material was insoluble. The
supernatant was applied to a Sephadex G-75 column (1.6 X 100
cm, Pharmacia) equilibrated and run with 4 M guanidine—0.1 M
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Fig. 1. Profile of the amyloid deposits after fractioned in 4 Mguanidine G-75
gel-filtration column. The second peak (small) corresponded to 132-micro-
globulin with a molecular weight of 12 kDa.
Tris. The column was calibrated with standard molecular weight
markers (bovine serum albumin, carbonic anhydrase, cytochrome
C, aprotinin; 66000, 29000, 12400, 6500 Da, respectively). Pooled
fractions (2 ml) were dialyzed exhaustively against distilled water,
and lyophilized.
Immunoblotting and protein sequence
Pooled fractions of the gel-filtration column were run on 17%
SDS-PAGE gel according to the method of Hashimoto et al [23].
The products were separated on SDS-PAGE according to the
discontinuous procedure of Schagger and Von Jagow with a three
layer gel [24]. Gels were stained in 0.1% Coomassie brilliant blue
and destained. The separated polypeptides on SDS-PAGE were
transferred to a nitrocellulose membrane according to the method
of Towbin, Staehlin and Gordon [251. The blot was subjected to
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Fig. 2. Seventeen percent SDS-PAGE gel with
three samples (lanes 2, 3 and 4, which
corresponded to patient 1, 2 and 3, respectively)
and standard (commercial) /32m in lane 1. The
major band (arrow) has a molecular weight of
12 kDa and corresponded to f32-microglobulin.
A minor bands could be observed with a
molecular weight of 25 kDa and 36 kDa,
corresponding to dimers and trimers of !2-
microglobulin.
dards, ovalbumin (44,000), carbonic anhydrase (27,900), p-lacto-
globulin (19,000), lysozyme (14,300), bovine trypsin inhibitor
(6,200), and insulin (3,000 Da).
Protein samples obtained from the major f32m band (12 kDa) of
the 17% SDS-PAGE gels were dissolved in water and applied to
BioBrene treated glass filters. Amino acid sequencing was carried
out using the standard O3RPTH program on a 470A gas-phase
sequencer equipped with a model 120 PTH analyzer. Protein
samples were studied using HPLC after protein digested with
trypsin. Commercial /32m (Behringwerke, Germany, 0.5 mg/mI)
was used as control for the HPLC procedure and SDS-PAGE
studies.
Results
Fig. 3. Western blotting of /32-micmglobulin from amyloid deposits. 2m was
transferred after migration in SDS-PAGE gel to a nitrocellulose mem-
brane and incubated with anti-human 2m. The Western blot analysis
confirmed the nature of this band, whieh was then microsequenced.
immunostaining using anti-human 2-microglobulin (1:1000; Da-
kopatts), followed by reaction with goat anti-rabbit conjugated
with alkaline phosphatase (Promega Corporation, WI, USA). The
blots were developed with 5-hromo-4-chloro-3-indolyl phosphate
and nitro-tetrazolium. The polyacrylamide gels and blots were
calibrated with low and high range prestained SDS-PAGE stan-
The solubilized amyloid fibrils which were fractionated in 4 ss
guanidine on a Sephadex G-75 column yielded two peaks for each
of the four studied samples (Fig. 1). The profiles obtained from
each of the four were similar with one void volume and one
retarded peak.
SDS-PAGE analysis of the first peak, after Coomassie blue
staining, showed seven bands of different molecular weights,
ranging from 25,000 to 180,000 Da. The lyophilized pool of this
peak identified the presence of several plasma proteinase inhibi-
tors (n1-proteinase inhibitor, 1-antichimotiypsin, antithrombin
III, a2-macroglobulin, and tissue metalloproteinase inhibitor) and
a small amount of f32m dimers irs the amyloid substance [26j.
Western blot analysis of different SDS-PAGE gels demonstrated
positive reactions with the antibodies directed against all of the
tested plasma proteinase inhibitors and 132m.
The second peak corresponded to a molecular weight of 12,000
to 25,000 Da, as determined by calibration of the filtration
6.2
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Table 2. Amino-terminal sequences of the f32-microgiobuhn isolated
from the four amyloid-laden tissues
Patient 1 Patient 2
Cycle A.A. pmol A.A. pmoi
Patient 3
AA. pmol
Patient 4
A.A. pmoi
1 lIe 120 lie 57 lie 84 lie 62
2 Gin 72 Gin 33 Gin 120 Gin 50
3 Arg 48 Arg 34 Arg 53 Arg 42
4 Thr 53 Thr 15 Thr 40 Thr 39
5 Pro 77 Pro 25 Pro 96 Pro 56
6 Lys 72 Lys — Lys 67 Lys 48
7 lIe 36 lie 33 lie 45 lie 30
8 Gin 58 Gin 24 Gin 64 Gin 39
9 Val 58 Vai 20 Val 70 Val 54
10 Tyr 41 Tyr 22 Tyr 58 Tyr 40
11 Ser 36 Ser 10 Ser 26 Ser 30
12 Arg 23 Arg 19 Arg 27 Arg 24
13 Flis 43 His 12 His 16 His 20
14 Pro 43 Pro 16 Pro 82 Pro 48
15 Ala 42 Ala 23 Ala 51 Ala 38
16 Glu 35 Glu 12 Glu 70 Glu 44
17 Asn 26 Asn 12 Asn 33 Asn —
18 Gly 23 Gly 15 Giy 24 Gly 20
19 Lys 32 Lys 6 Lys 45 Lys 28
20 Ser 17 Ser 10 Ser 17 Ser 14
21 Asn 20 Asn 8 Asn 35 Asn 18
22 Phe 22 Phe 12 Phe 35 Phe 28
23 Leo 17 Leo 7 Leu 38 Leo 18
24 Asn 14 Asn 7 Asn 35 Asn 12
25 (Cys) — (Cys) — (Cys) — (Cys)
26 Tyr 15 Tyr 6 Tyr 35 Tyr 20
27 Val 14 Val 7 Val 38 Vai 22
28 Ser 13 Ser 8 Ser ii (Ser) —
29 Gly 12 Gly 13 Gly 10
30 Phe 12 X Phe 8
31 His 3 His — (His)
32 Pro 15 Pro 6 Pro 8
33 (Ser) —
34 Asp 13
35 lie 6
36 Glu 7
37 Val 10
38 Asp 12
39 Lcu 7
40 Leu 12
Parenthesis indicate a suspected residue;
that cannot be positively identified. In patien
X indicates
t 2, Lys at res
a PTH-derivate
idue 6 could not
be quantified due to machine error.
column. This molecular weight was also confirmed by gel electro-
phoresis on a 17% SDS-PAGE gel, which demonstrated, under
reducing conditions, one major band at 12,000 kDa and a minor
band at 25,000 Da. No bands of lower molecular weight were
noted in the 17% SDS-PAGE gels (Fig. 2). Moreover, the three
layer gels discarded the presence of lower molecular weight
bands. Western blot analysis with anti-human-2m confirmed the
2m nature of the two bands (monomer and dimer) obtained from
the second gel filtration peak (Fig. 3). No low molecular weight
132m fragments were identified in the Western blot analysis.
The 12 kDa band was micro-sequenced and the amino acid
sequence corresponded to that of normal f32m through the 40th
residue. Protein sequencing was carried out to 40th, 32nd, 28th
and 32nd residues for samples from patients 1, 2, 3 and 4,
respectively (Table 2). No amino acid sequence differences from
the normal /32m [27] were observed in any of the isolated f32m
proteins from the amyloid fibrils. The amino terminus began only
with one signal in each of the preparations. The HPLC profile of
the four protein samples were strictly normal and identical to a
commercial preparation of 2m (Fig. 4).
Discussion
The present study demonstrates that the 132m molecules poly-
merized in amyloid fibrils and deposited in osteo-articular and
visceral tissues of dialysis patients are intact and normal. We
could not identify any f32m fragment in the amyloid deposits, and
no amino acid sequence alterations were observed in any of the
four amyloid-laden tissues examined. Using a gel-filtration col-
umn, SDS-PAGE gels, immunoblotting technique, HPLC proce-
dure and amino acid sequencing, all the /32m present in the
studied amyloid deposits have an apparently normal molecular
weight, a completely normal amino acid sequence, and were not
fragmented.
These data support other studies suggesting that 2m amyloid
fibrils and deposits are composed essentially of normal and intact
132m, and are produced by a specific and unique fibrillogenetic
mechanism in patients on long-term dialysis therapy, which does
not require proteolytic processing from the precursor protein to
the amyloid fibrils [7, 9]. The finding that f32m in amyloid deposits
is intact and not fragmented reinforces the data of the in vitro
studies, in which f32m amyloid fibrils were spontaneously created.
Connors et at demonstrated the spontaneous generation of f32m
amyloid fibrils from the native protein with a high /32m concen-
tration in a salt-free solution [28]. We also documented, using
light, electron and immunoelectron microscopy, the spontaneous
formation of /32m amyloid fibrils in the supernatants of peripheral
blood mononuclear cell culture from dialysis patients [29]. In both
studies J32m amyloid fibrils were created without a proteolytic
process, and found to have an intrinsic amyloidogenic capacity.
These studies demonstrated the high affinity of f32m to polymerize
in amyloid fibriis, and that the inherent beta structure of 132m is
important in the fibrillogenesis process.
The presence and relevance of acidic f32m isoforms in the
pathogenesis of A/32m amyloidosis have been a controversial issue
since the identification of diaiysis-amyioidosis. In 1977, Hall,
Ricanati and Vacca reported the presence of 132m with a 5.33 p1
in the urine of transplant patients and healthy subjects [30].
Gorevic et al defined for the first time the heterogeriicity in charge
of the /32m isolated from amyloid deposits of dialysis patients, with
a predominance of acidic forms, suggesting a role in the f32m
amyloidogenesis proccess [101. Odani et at reported the amino
acid sequence analysis of the acidic /32m isoform with a 5.22 p1
named "novel 2m," and they found a single amino acid replace-
ment, a deamination in the 17th residue [15]. However, two
different groups recently confirmed the presence of several /32m
acidic isoforms in /32m amyioid deposits, although all the isoforms
purified were intact and identical in their N-terminal side [18, 191.
They also demonstrated that these more acidic f32m isoforms are
not specific to A132m amyloidosis, since they were present in
healthy subjects and in dialysis patients without evidence of A2m
amyloidosis. These data reinforce the results of the present study,
and we could conclude that 2m in amyloid deposits is essentially
normal, not fragmented, and has a predominance of acidic
isoforms.
Miyata Ct al recently demonstrated that the acidic 2m is
generated by modification with advanced glycation end products
(AGEs), implicating a potential link of this modified 2m to the
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Fig. 4. Nonnal HPLC profile of the isolated /32-microglobulin from the amyloid deposits (Sample from patient # 1).
pathogenesis of dialysis-amyloidosis [20, 21]. This study demon-
strated that a major portion of 2m forming amyloid fibrils
exhibited unusual electrophoretic mobility, with a more acidic p1
value than normal 2m. They purified 2m from the urine of
long-term dialysis patients to homogeneity and observed that the
acidic isoform resulted from advanced glycation end modification,
and that it represents the dominant isoform of f32m in amyloid
deposits of dialysis-amyloidosis. AGE-modified f32m could favor
the 2m amyloidogenesis process at several levels: enhancing the
chemotaxis and chemokinesis of monocytes; stimulating macro-
phages to secrete inflammatory cytokines such as TNF-a and
lL-1/3; inducing the synthesis of collagenase from synovial cells;
and functions as a stimulator for bone resorption and as an
inhibitor of bone formation at the site of the amyloid deposit [211.
All these findings suggest that AGE-132m participates in the
pathogenesis of dialysis-amyloidosis as foci where macrophages-
monocytes accumulate and initiate an inflammatory response that
leads to bone and joint destruction. Moreover, during hemodial-
ysis, especially with cellulosic membranes, enhanced production
of these cytokines (TNF-a, IL-1/3) is well documented [31, 32].
These cytokines subsequently could stimulate synovial cells to
secrete collagenase that degrades collagen, resulting in further
migration of the inflammatory cells into amyloid deposits and the
production of more inflammatory cytokines [21, 33, 34]. Also, 132m
has been shown to he able to directly promote bone remodeling
and to induce the synthesis of fibroblast collagenase, suggesting its
role in modulating connective tissue breakdown in both normal
and disease states [35—37]. The high levels of these collagenolysis
inducers lead to high levels of collagenase in synovial fluid, with
excessive collagen breakdown, and could predispose the polymer-
ization of f32m in amyloid fibrils. Moreover, chronic renal failure
and hemodialysis treatment induce high levels of other proteolytic
enzymes such as neutrophil elastase and cathepsin G, which could
facilitate the osteo-articular lesion [38]. The inflammatory activity
present in the synovial fluid of dialysis patients with high levels of
proteolytic enzymes (collagenase, elastase and cathepsin G) may
be responsible for the presence of a2-macroglobulin and other
plasma proteinase inhibitors, in the synovial tissues affected by
f32m amyloid deposits [26, 39].
In summary, in a milieu with a very high enzymatic activity
(collagenase, elastase and cathepsin G), increased bone resorp-
tion activity, and intrinsic metabolic alteration of bone structure,
it is reasonable to think that collagen fibril surfaces will be
exposed to the high levels of 2m in the synovial fluid. If we add
the intrinsic amyloidogenic capacity of /32m and its high affinity for
collagen-rich tissues [40], all these factors acting together could
explain the specific and unique fibrillogenesis process of A2m
amyloidosis, in which a post-translational change of a completely
normal plasma protein could favor the polymerization into amy-
bid fibrils without a previous proteolytic process, and the striking
predisposition of Ap2m amyloidosis for osteo-articular structures.
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